On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...
A new editorial was published in Volume 18 of Aging-US on February 8, 2026, titled "Polyploidy-induced senescence: Linking development, differentiation, repair, and (possibly) cancer?" In this ...
The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...
Urological cancers, encompassing malignancies of the prostate, bladder, kidney, and testicles, present significant clinical challenges due to their ...